ArticleAntonie van Leeuwenhoek2026
Antibacterial activity of marine macroalgae-associated Bacillus spp. from the Bay of Bengal coast of India.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The marine macroalgal holobiont evolved as a functional unit by establishing a mutualistic relationship between the host and its associated microbiomes, enabling both partners to achieve ecological success. In the present study, we evaluated the antibacterial activity of marine macroalgae-associated endophytic Bacillus spp. based on microbiological assay and profiling of non-targeted extracellular metabolites using liquid chromatography/electrospray ionization-mass spectrometry (LC/ESI-MS) analysis. The antibacterial activity of 76 bacterial endophytes isolated from 32 macroalgal samples of nine genera, including green, red, and brown algae, was evaluated in this study by employing a spot-on-overlay assay against four bacterial strains, i.e., Escherichia coli MTCC9537, Klebsiella pneumoniae MTCC109, Pseudomonas aeruginosa MTCC741, and Staphylococcus aureus MTCC7443. Seventeen strains of five different Bacillus species (i.e., B. aerius, B. pumilus, B. safensis, B. stercoris, B. stratosphericus) showed antibacterial activity at least against one bacterial pathogen. Out of 17 antibacterial positive isolates, 13, 9, 5, and 3 isolates showed the zone of inhibition against E. coli MTCC9537 (28.13 ± 7.82 mm), K. pneumoniae MTCC109 (29.2 ± 5.38 mm), P. aeruginosa MTCC741 (28.0 ± 6.71 mm), and S. aureus MTCC7443 (26.21 ± 10.88 mm), respectively. The LC/ESI-MS analysis of ethyl acetate crude extracts of extracellular metabolites secreted by three Bacillus species (i.e., B. pumilus RS45_EN1, B. stratosphericus RK15_EN4, and B. aerius RS70_EN1) detected four different antibacterial compounds, including 2-heptyl-4-hydroxyquinoline N-oxide, 4-hydroxybenzoic acid, dibutyl phthalate, and myristoleic acid. Our study suggests that macroalgae-associated Bacillus spp. could be a potential source for antibacterial compounds.
Indexed as
Identifiers
42749949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.